Abrdn Life Sciences Investors (HQL)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Daniel R. Omstead M.S, Ph.D. | Principal Executive Officer, President and Trustee | -- | -- | 1953 |
| Mr. Peter Branner | Chief Investment Officer | -- | -- | -- |
Abrdn Life Sciences Investors
- Sector:
- Financial Services
- Industry: Asset Management
Description
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Corporate Governance
Recent Events
- Apr 22, 2024DEF 14A: Proxy StatementsSee Full Filing
- Apr 17, 2024SC 13D/A: Tender Offer/Acquisition ReportsSee Full Filing
- Feb 29, 2024NPORT-P: Monthly Portfolio Investments Report on Form N- PORT (Public)See Full Filing
- Feb 21, 2024Ex-Dividend Date
- Feb 07, 2024SC 13D/A: Tender Offer/Acquisition ReportsSee Full Filing